Investment area
Seed Investments
Region
Europe
Date of investment
August 2020
Rappta Therapeutics is working on a first-in-class series of anti-cancer molecules that reactivate a key tumor suppressor, protein phosphatase 2A (PP2A). Rappta’s proprietary tools and understanding of the target allow them to therapeutically reactivate PP2A, a critical enzyme regulating protein de-phosphorylation and tumor growth. As a result of PP2A’s central role in the regulation of protein phosphorylation, Rappta’s PP2A-reactivating technologies have platform potential in human therapeutic use.
Contact
Jeroen Bakker
Partner
Department: Seed Investments
Jeroen Bakker joined Seed Investments in 2018.
Jeroen currently holds several board roles and led the investment in Adcendo and Rappta Therapeutics. Prior to joining Novo, Jeroen worked at M Ventures, the corporate venture capital arm of Merck, where he focused on Seed and Series A investments across Europe, United States Israel. He was instrumental in the Artsavit Ltd investment and served on multiple boards. Jeroen held a variety of operational biotech roles in companies like Syntaxin (acquired by Ipsen), Inthera and ISD Immunotech. Prior to joining biotech, he was a Research Fellow at the La Jolla Institute for Allergy and Immunology in San Diego.
Jeroen holds a PhD in Immunology from the University of Amsterdam, an MSc in Biomedical Sciences from the Leiden University with a specialization in entrepreneurship and an BSc from the Technical University of Delft. Jeroen was chair of the Dutch Platform for Young Researchers in Nephrology and a member of REBBLS, a Danish networking organization focusing on young biotech entrepreneurs.
